All News

The findings, according to the lead study author, demonstrate that treatment with forimtamig delivered intravenously or subcutaneously may elicit long-term responses in patients with relapsed or refractory multiple myeloma.

The 5-year follow-up of the phase 3 AUGMENT trial produced enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Patients with penta-or triple-class refractory multiple myeloma who have not received prior B-cell maturation antigen therapy saw an improved objective response rate when elranatamab was given.

Patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia, chronic phase, or acute phase who are resistant to tyrosine kinase inhibitors were found to show a clinical benefit with olvermbatinib.

A potential efficacy benefit has been observed with lintuzumab-Ac225 plus salvage therapy for patients with relapsed/refractory acute myeloid leukemia.

Findings from the phase 1b MajesTEC-2 trial indicated that teclistamab in combination with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.

The phase 3 ASAP trial found the use of watchful waiting followed by sequential conditioning prior to allogeneic hematopoietic cell transplantation found a similar survival benefit in patients with relapsed/refractory acute myeloid leukemia.

The use of two separate recommended phase 2 doses of talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma, according to updated trial findings presented at 2022 American Society of Hematology Annual Meeting.

The use of a fixed-duration regimen of glofitamab several days after pretreatment with obinutuzumab was associated with high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Patients with HER2-positive metastatic breast cancer experienced promising preliminary safety and efficacy with trastuzumab deruxtecan alone and in combination with pertuzumab.

Improvements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.

Adults and children with unresectable or metastatic alveolar soft part sarcoma—one of the rarest types of sarcoma—can now receive treatment with atezolizumab, which was given the nod of approval by the FDA.

Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.

Long-term findings from the phase 2 GeparOLA trial indicate that olaparib plus paclitaxel and carboplatin did not result in further benefit vs paclitaxel, and carboplatin for patients with HER2-negative, homologous recombination–deficient early breast cancer.

Robert Mutter, MD, of Mayo Clinic says that proton postmastectomy radiation therapy allows for excellent tissue sparing in the management of breast cancer.

Patients with multiple ipsilateral breast cancer might benefit from having a preoperative MRI before proceeding with breast conservation therapy, according to Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota.

Results from the phase 3 STIC CTC trial found an improved overall survival when circulating tumor cells were used as a guide in combination with chemotherapy or endocrine therapy in patients with hormone receptor–positive/HER2-negative breast cancer.

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant.

Patients with ER-positive/HER2-negative metastatic breast cancer had improved progression-free survival when treated with elacestrant compared with standard of endocrine therapy.

Results from the real-world analysis of the phase 2 HER2CLIMB trial showed a good safety profile with the tucatinib triplet regimen in patients with HER2-positive metastatic breast cancer.

ARV-471 monetherapy showed clinical benefit in an expansion cohort of patients with locally advanced or metastatic breast cancer, according to data from the VERITAC trial.

Treatment with a range of camizestrant monotherapy doses resulted in a survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

Patients with HER2-low or HER2-0 metastatic breast cancer who previously received at least 1 chemotherapy agent garnered similar benefit from eribulin mesylate vs standard physician's choice chemotherapies.

Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Trastuzumab deruxtecan improved survival outcomes vs trastuzumab emtasine in patients with HER2-positive breast cancer, according to updated results from the DESTINY-Breast03 trial.

Data from the phase 2 TRIO-US B-12 TALENT trial indicate that fam-trastuzumab deruxtecan-nkxi in the neoadjuvant setting with or without endocrine therapy could be beneficial for patients with hormone receptor–positive, HER2-low breast cancer.

Yoga and conventional exercises also demonstrated long-term improvement in quality of life during treatment for non-metastatic breast cancer, according to results presented at the 2022 San Antonio Breast Cancer Symposium.

Patients with advanced HER2-positive breast cancer had improved progression-free and overall survival when treated with trastuzumab deruxtecan compared with capecitabin-based treatment, according to recent findings.

Experts believe that use of the Breast Cancer Index test in patients with early-stage, hormone receptor–positive breast cancer who are undergoing treatment with endocrine therapy may help to identify those who could be good candidates for the addition of ovarian function suppression.

The phase RIGHT Choice trial yield a 46% reduction in disease progression when ribociclib was added to endocrine therapy for patients with pre/perimenopausal hormone-receptor–positive/HER2-negative advanced breast cancer.